Ulazzi et al., [30] were the first group to demonstrate NID2 methylation in a cancer specific manner, in human gastrointestinal cancer; promoter hypermethylation of NID2 was shown in 14 out of 48 colon carcinoma samples analyzed compared to 0/24 normal colon, 19/20 of the gastric carcinomas, and 0/13 normal gastric mucosa. This evidence concerns the gene NID2 and cancer.